AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04410523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.
Study NCT04410523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.
Study NCT04150614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Transdermal Patch
Description: Antiemetic
Study NCT04150614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Description: Antiemetic
Study NCT04150614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron
Study NCT04476862 — intervention group
Intervention type: DRUG
Intervention: Cerliponase Alfa
Description: Commercially available product provided to patient by participating clinic site.
Study NCT04476862 — intervention group
Intervention type: DEVICE
Intervention: Administration Kit
Description: Commercially available administration kit provided to the patient by participating clinic site.
Study NCT01727284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-guided cryoablation
Study NCT04008745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and home-based physical therapy by foot-related exercises
Description: The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
Study NCT04097678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retained Surgical Sponge
Description: A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
Study NCT03350529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided transurethral HIFU ablation of prostatic tissue
Description: The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
Study NCT02731638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrastromal voriconazole
Description: Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
Study NCT02731638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natamycin
Description: Subjects will receive topical 5% natamycin drops hourly for 3 days.
Study NCT02731638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natamycin
Description: Subjects will receive topical 5% natamycin drops hourly for 3 days.
Study NCT04091048 — intervention group
Intervention type: DEVICE
Intervention: Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Description: Aortic valve replacement
Study NCT02340026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Supported Mobility
Description: Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
Study NCT02340026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child
Study NCT01436149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate )
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Study NCT01436149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Study NCT01058980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional ablation until elimination of dormant conduction
Description: Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
Study NCT01058980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No additional ablation
Description: Presence of dormant PV conduction, no additional ablation.
Study NCT01058980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Registry group
Description: Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
Study NCT01058980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
Study NCT02380573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Study NCT02380573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FD&C Blue # 2
Study NCT02380573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine hydrochloride
Study NCT02380573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenazopyridine hydrochloride
Study NCT00996476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
Study NCT04080661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.
Study NCT04080661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Description: The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
Study NCT03286036 — intervention group
Intervention type: OTHER
Intervention: biomarkers
Description: This is an observational study, there is no intervention
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, or PO
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04216524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04216524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04216524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT06281587 — intervention group
Intervention type: PROCEDURE
Intervention: penetrating keratoplasty
Description: replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.
Study NCT00996476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a
Description: One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
Study NCT02663492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
Study NCT02663492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanguisorba officinalis L.
Description: Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
Study NCT03244878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive
Description: A interactive computerized program using structured content of cognitive behavior therapy
Study NCT04044950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR
Description: The injection will be approximately 3x10\^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B™ vaccine
Description: Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B™ vaccine
Description: Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix/Hib™ vaccine
Description: Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix/Hib™ vaccine
Description: Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™ vaccine
Description: Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™ vaccine
Description: Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™ vaccine
Description: Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™ vaccine
Description: Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™ vaccine
Description: Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™ vaccine
Description: Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine
Description: Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
Study NCT01345240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine
Description: Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
Study NCT03995368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
Study NCT01502293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.
Study NCT01502293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Study NCT02673372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
Study NCT02673372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
Study NCT01707342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (TMC435)
Description: Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
Study NCT03162146 — intervention group
Intervention type: OTHER
Intervention: Deaths in intensive care unit
Description: Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
Study NCT04768738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation Level Of Above Threshold
Description: Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
Study NCT04768738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation Level Of Subthreshold
Description: biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
Study NCT04768738 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular Vagus Nerve Stimulation Sham Method
Description: Participants were shown that the device was working, but no current was given.
Study NCT04768738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 5 Minutes Bicycle Exercise
Description: Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
Study NCT04768738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: 5 Minutes Bicycle Exercise
Description: Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 60 ml heparinized blood 10 ml serum
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample
Description: pea-sized amount
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: 10 ml
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoalveolar Lavage (BAL) fluid
Description: 10 ml
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastrointestinal biopsy x 2-4
Description: rectosigmoid site preferred
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: 2-4 mm punch
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin, mouth, and/or ocular swab
Description: Involved skin, mouth, and/or ocular swab for microbiota studies
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Apheresis Product
Description: Up to 10 ml of apheresis product
Study NCT03557749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Final cellular product
Description: A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
Study NCT03160261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Injection
Description: Single injection of Exenatide 10μg subcutaneously
Study NCT02480972 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: magnetic resonance imaging
Description: multiparametric MRI as follows:~1. diffusion weighted imaging using multiple b-values~2. Fat quantification sequence~3. perfusion MRI using ECCM agent~4. MR elastography~   ------------------------------------~5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)
Study NCT06183762 — intervention group
Intervention type: OTHER
Intervention: No treatment is included in this protocol.
Description: No drug intervention or tissue sampling will be included in this study.
Study NCT00996476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.